momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (11128)	6/6/2017 10:06:46 PM
From: Miljenko Zuanic	Read Replies (1) of 12215

<I know MZ followed VKTX, perhaps he has a view on VK2809?> Yes, VK2809 and MGL-3196 target is the same thyroid hormone receptor-beta (agonist, activator), expressed on liver. As Tuck pointed, side effects can be problematic and so far hindered development of this drug-type. I do not know for MGL-3196, but VK2809 is liver-specific ????( pro-drug, activated by liver enzyme????), so maybe there is hope that 5/10 mg dose may open Therapeutic Window and have positive data in PII trial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next